Oxford AstraZeneca coronavirus vaccine gains EU authorization for all adults



Although there is insufficient evidence about the effectiveness of the Oxford-AstraZeneca vaccine, the European Union’s (EU) regulator the European Medicines Agency has finally authorized its use in all 27 countries in the block. Both Britain and India had already approved it. The U.S. has not as yet approved it.


EU Officials have raised concerns on the small number of older participants in clinical trials. The six percent concentration is minimal when accounting for the fact that they constitute the age group which has the highest number of deaths related to the virus as well being the group that is prioritized to receive the vaccines.


There is a tussle between the EU and Britain as the company believes it will fall short of the expected deliveries. Problems at a manufacturing site in Belgium has created legal problems as EU officials are preparing for a possible visit to the site.


Brussels is expecting  a share in supplies from British publishing sites according to its contract with the company as the use of other manufacturing sites, when necessary, is a part of the contract. Britain has not faced any shortages.


Statistics in the EU are dismal as less than 2% of its population which is around 450 million has been vaccinated and some of them have received only one dose in these two dose vaccines. Germany has already mentioned shortages.


The burgeoning problems of shortage of vaccines while transmission rates are spring has made the EU contemplate taking legal actions to surmount the shortage. German health minister Jens Spahn said that the company has recently indicated it will meet the shortfall.


However, Spahn also said that the way out of the “pandemic of the century” has started and the fact that there are three vaccines in the EU in just above 12 months is a “unique success story in medicine.”


Although the EU had pre-ordered vaccines from many other suppliers including Pfizer-BioNTech and Moderna, it has miscalculated these amounts. It has now increased the order amount up to 600 million doses.


Follow us on Google news for more updates and News


This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer